Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded pharmaceutical products. The Company markets a portfolio of branded products, including: SILENOR®, a non-narcotic product for the treatment of insomnia, and KHEDEZLA™, as well as CEDAX®, an antibiotic for middle ear infections and a number of treatments for cough and cold conditions including ZUTRIPRO®, REZIRA® and VITUZ®. The Company promotes its branded products to physicians through its Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. Founded in 1996, the Company is now based in Morristown, New Jersey.
PERNIX THERAPEUTICS APPOINTS CHIEF FINANCIAL OFFICER
PERNIX signs agreement to acquire TREXIMET® Tablets for Migraine from GSK
PERNIX THERAPEUTICS TO REPORT FIRST QUARTER 2014 FINANCIAL RESULTS ON MAY 12, 2014
Pernix Therapeutics’ family of branded prescription products are well-recognized and a highly prescribed portfolio of core marketed products. Our products are developed to meet the needs of patients and physicians by focusing on safe, unique and effective products for treating common medical conditions.
Our pediatric division has a solid track record in promoting the established brands of CEDAX® (ceftibuten) Suspension, CEDAX® (ceftibuten) Capsules and Natroba® (spinosad) Topical Solution. Pediatricians trust our products to treat their patients for conditions they see on a daily basis, including acute otitis media, asthma, allergies, upper respiratory ailments and lice.
Pernix’s line of primary care products offers the physician choices in treating common ailments of the adult patient. ZUTRIPRO® (hydrocodone bitartrate, pseudoephedrine HCl, chlorpheniramine maleate) Oral Solution, Silenor® (doxepin) Tablets, and Omeclamox-Pak® (omeprazole, clarithromycin, amoxicillin) are a few of the primary care products Pernix Therapeutics offers.
Pernix markets its generic products through its wholly-owned subsidiaries, Macoven Pharmaceuticals and Cypress Pharmaceutical. Sales of generic products represented 36% of the net revenues of Pernix for the year ended December 31, 2012. The generic product portfolios include the areas of antibiotics, respiratory care, dermatology, pain, gastroenterology, dental health and vitamins.